BridgeBio Pharma expands its research into neuromuscular disease to include Limb-Girdle Muscular Dystrophy Type 2 (LGMD2i) with new subsidiary ML Bio SolutionsGlobeNewsWire • 09/05/19
Adaptive Biotech and BridgeBio shares rocket higher on their first day of tradeMarket Watch • 06/27/19